Industry Research Reports

Home > Reports > Pharma & Healthcare > Cancer Immunotherapy Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Cancer Immunotherapy Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Pharma & Healthcare

Published: 2024-02-19

Pages: 137 Pages

Report ld: 2517055

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Cancer Immunotherapy Drugs are medications used in the treatment of cancer. These drugs harness the body's immune system to target and destroy cancer cells. Immunotherapy drugs are designed to boost the body's natural defenses against cancer and are used in various forms, including immune checkpoint inhibitors and CAR-T cell therapies.

The global market for Cancer Immunotherapy Drug was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Cancer Immunotherapy Drug, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Cancer Immunotherapy Drug by region & country, by Type, and by Application.

The Cancer Immunotherapy Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Immunotherapy Drug.

Market Segmentation

Report Metric
Details
Report Title
Cancer Immunotherapy Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global Cancer Immunotherapy Drug Companies Covered
Autolus Therapeutics plc, BeiGene, bluebird bio, Inc., Bristol-Myers Squibb, Celgene Corporation, AstraZeneca plc, Gilead Sciences, Inc., Incyte Corporation, Jiangsu Hengrui Medicine, Juno Pharmaceuticals Pty Ltd., Medimmune, LLC, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Roche Holding AG
Global Cancer Immunotherapy Drug Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cancer Immunotherapy Drug Market, Segment by Type
PD-1 Inhibitor

PDL-1 Inhibitor

T-Cell Stimulant

CTLA Antibody
Global Cancer Immunotherapy Drug Market, Segment by Application
Hospital

Clinic

Others
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cancer Immunotherapy Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Cancer Immunotherapy Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Cancer Immunotherapy Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Cancer Immunotherapy Drug Product Introduction
    1.2 Global Cancer Immunotherapy Drug Market Size Forecast
        1.2.1 Global Cancer Immunotherapy Drug Sales Value (2019-2030)
        1.2.2 Global Cancer Immunotherapy Drug Sales Volume (2019-2030)
        1.2.3 Global Cancer Immunotherapy Drug Sales Price (2019-2030)
    1.3 Cancer Immunotherapy Drug Market Trends & Drivers
        1.3.1 Cancer Immunotherapy Drug Industry Trends
        1.3.2 Cancer Immunotherapy Drug Market Drivers & Opportunity
        1.3.3 Cancer Immunotherapy Drug Market Challenges
        1.3.4 Cancer Immunotherapy Drug Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Cancer Immunotherapy Drug Players Revenue Ranking (2023)
    2.2 Global Cancer Immunotherapy Drug Revenue by Company (2019-2024)
    2.3 Global Cancer Immunotherapy Drug Players Sales Volume Ranking (2023)
    2.4 Global Cancer Immunotherapy Drug Sales Volume by Company Players (2019-2024)
    2.5 Global Cancer Immunotherapy Drug Average Price by Company (2019-2024)
    2.6 Key Manufacturers Cancer Immunotherapy Drug Manufacturing Base Distribution and Headquarters
    2.7 Key Manufacturers Cancer Immunotherapy Drug Product Offered
    2.8 Key Manufacturers Time to Begin Mass Production of Cancer Immunotherapy Drug
    2.9 Cancer Immunotherapy Drug Market Competitive Analysis
        2.9.1 Cancer Immunotherapy Drug Market Concentration Rate (2019-2024)
        2.9.2 Global 5 and 10 Largest Manufacturers by Cancer Immunotherapy Drug Revenue in 2023
        2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Immunotherapy Drug as of 2023)
    2.10 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 PD-1 Inhibitor
        3.1.2 PDL-1 Inhibitor
        3.1.3 T-Cell Stimulant
        3.1.4 CTLA Antibody
    3.2 Global Cancer Immunotherapy Drug Sales Value by Type
        3.2.1 Global Cancer Immunotherapy Drug Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Cancer Immunotherapy Drug Sales Value, by Type (2019-2030)
        3.2.3 Global Cancer Immunotherapy Drug Sales Value, by Type (%) (2019-2030)
    3.3 Global Cancer Immunotherapy Drug Sales Volume by Type
        3.3.1 Global Cancer Immunotherapy Drug Sales Volume by Type (2019 VS 2023 VS 2030)
        3.3.2 Global Cancer Immunotherapy Drug Sales Volume, by Type (2019-2030)
        3.3.3 Global Cancer Immunotherapy Drug Sales Volume, by Type (%) (2019-2030)
    3.4 Global Cancer Immunotherapy Drug Average Price by Type (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Hospital
        4.1.2 Clinic
        4.1.3 Others
    4.2 Global Cancer Immunotherapy Drug Sales Value by Application
        4.2.1 Global Cancer Immunotherapy Drug Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Cancer Immunotherapy Drug Sales Value, by Application (2019-2030)
        4.2.3 Global Cancer Immunotherapy Drug Sales Value, by Application (%) (2019-2030)
    4.3 Global Cancer Immunotherapy Drug Sales Volume by Application
        4.3.1 Global Cancer Immunotherapy Drug Sales Volume by Application (2019 VS 2023 VS 2030)
        4.3.2 Global Cancer Immunotherapy Drug Sales Volume, by Application (2019-2030)
        4.3.3 Global Cancer Immunotherapy Drug Sales Volume, by Application (%) (2019-2030)
    4.4 Global Cancer Immunotherapy Drug Average Price by Application (2019-2030)

 5 Segmentation by Region
    5.1 Global Cancer Immunotherapy Drug Sales Value by Region
        5.1.1 Global Cancer Immunotherapy Drug Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Cancer Immunotherapy Drug Sales Value by Region (2019-2024)
        5.1.3 Global Cancer Immunotherapy Drug Sales Value by Region (2025-2030)
        5.1.4 Global Cancer Immunotherapy Drug Sales Value by Region (%), (2019-2030)
    5.2 Global Cancer Immunotherapy Drug Sales Volume by Region
        5.2.1 Global Cancer Immunotherapy Drug Sales Volume by Region: 2019 VS 2023 VS 2030
        5.2.2 Global Cancer Immunotherapy Drug Sales Volume by Region (2019-2024)
        5.2.3 Global Cancer Immunotherapy Drug Sales Volume by Region (2025-2030)
        5.2.4 Global Cancer Immunotherapy Drug Sales Volume by Region (%), (2019-2030)
    5.3 Global Cancer Immunotherapy Drug Average Price by Region (2019-2030)
    5.4 North America
        5.4.1 North America Cancer Immunotherapy Drug Sales Value, 2019-2030
        5.4.2 North America Cancer Immunotherapy Drug Sales Value by Country (%), 2023 VS 2030
    5.5 Europe
        5.5.1 Europe Cancer Immunotherapy Drug Sales Value, 2019-2030
        5.5.2 Europe Cancer Immunotherapy Drug Sales Value by Country (%), 2023 VS 2030
    5.6 Asia Pacific
        5.6.1 Asia Pacific Cancer Immunotherapy Drug Sales Value, 2019-2030
        5.6.2 Asia Pacific Cancer Immunotherapy Drug Sales Value by Country (%), 2023 VS 2030
    5.7 South America
        5.7.1 South America Cancer Immunotherapy Drug Sales Value, 2019-2030
        5.7.2 South America Cancer Immunotherapy Drug Sales Value by Country (%), 2023 VS 2030
    5.8 Middle East & Africa
        5.8.1 Middle East & Africa Cancer Immunotherapy Drug Sales Value, 2019-2030
        5.8.2 Middle East & Africa Cancer Immunotherapy Drug Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Cancer Immunotherapy Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Cancer Immunotherapy Drug Sales Value
        6.2.1 Key Countries/Regions Cancer Immunotherapy Drug Sales Value, 2019-2030
        6.2.2 Key Countries/Regions Cancer Immunotherapy Drug Sales Volume, 2019-2030
    6.3 United States
        6.3.1 United States Cancer Immunotherapy Drug Sales Value, 2019-2030
        6.3.2 United States Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Cancer Immunotherapy Drug Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Cancer Immunotherapy Drug Sales Value, 2019-2030
        6.4.2 Europe Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Cancer Immunotherapy Drug Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Cancer Immunotherapy Drug Sales Value, 2019-2030
        6.5.2 China Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Cancer Immunotherapy Drug Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Cancer Immunotherapy Drug Sales Value, 2019-2030
        6.6.2 Japan Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Cancer Immunotherapy Drug Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Cancer Immunotherapy Drug Sales Value, 2019-2030
        6.7.2 South Korea Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Cancer Immunotherapy Drug Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Cancer Immunotherapy Drug Sales Value, 2019-2030
        6.8.2 Southeast Asia Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Cancer Immunotherapy Drug Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Cancer Immunotherapy Drug Sales Value, 2019-2030
        6.9.2 India Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Cancer Immunotherapy Drug Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Autolus Therapeutics plc
        7.1.1 Autolus Therapeutics plc Company Information
        7.1.2 Autolus Therapeutics plc Introduction and Business Overview
        7.1.3 Autolus Therapeutics plc Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2019-2024)
        7.1.4 Autolus Therapeutics plc Cancer Immunotherapy Drug Product Offerings
        7.1.5 Autolus Therapeutics plc Recent Development
    7.2 BeiGene
        7.2.1 BeiGene Company Information
        7.2.2 BeiGene Introduction and Business Overview
        7.2.3 BeiGene Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2019-2024)
        7.2.4 BeiGene Cancer Immunotherapy Drug Product Offerings
        7.2.5 BeiGene Recent Development
    7.3 bluebird bio, Inc.
        7.3.1 bluebird bio, Inc. Company Information
        7.3.2 bluebird bio, Inc. Introduction and Business Overview
        7.3.3 bluebird bio, Inc. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2019-2024)
        7.3.4 bluebird bio, Inc. Cancer Immunotherapy Drug Product Offerings
        7.3.5 bluebird bio, Inc. Recent Development
    7.4 Bristol-Myers Squibb
        7.4.1 Bristol-Myers Squibb Company Information
        7.4.2 Bristol-Myers Squibb Introduction and Business Overview
        7.4.3 Bristol-Myers Squibb Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2019-2024)
        7.4.4 Bristol-Myers Squibb Cancer Immunotherapy Drug Product Offerings
        7.4.5 Bristol-Myers Squibb Recent Development
    7.5 Celgene Corporation
        7.5.1 Celgene Corporation Company Information
        7.5.2 Celgene Corporation Introduction and Business Overview
        7.5.3 Celgene Corporation Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2019-2024)
        7.5.4 Celgene Corporation Cancer Immunotherapy Drug Product Offerings
        7.5.5 Celgene Corporation Recent Development
    7.6 AstraZeneca plc
        7.6.1 AstraZeneca plc Company Information
        7.6.2 AstraZeneca plc Introduction and Business Overview
        7.6.3 AstraZeneca plc Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2019-2024)
        7.6.4 AstraZeneca plc Cancer Immunotherapy Drug Product Offerings
        7.6.5 AstraZeneca plc Recent Development
    7.7 Gilead Sciences, Inc.
        7.7.1 Gilead Sciences, Inc. Company Information
        7.7.2 Gilead Sciences, Inc. Introduction and Business Overview
        7.7.3 Gilead Sciences, Inc. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2019-2024)
        7.7.4 Gilead Sciences, Inc. Cancer Immunotherapy Drug Product Offerings
        7.7.5 Gilead Sciences, Inc. Recent Development
    7.8 Incyte Corporation
        7.8.1 Incyte Corporation Company Information
        7.8.2 Incyte Corporation Introduction and Business Overview
        7.8.3 Incyte Corporation Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2019-2024)
        7.8.4 Incyte Corporation Cancer Immunotherapy Drug Product Offerings
        7.8.5 Incyte Corporation Recent Development
    7.9 Jiangsu Hengrui Medicine
        7.9.1 Jiangsu Hengrui Medicine Company Information
        7.9.2 Jiangsu Hengrui Medicine Introduction and Business Overview
        7.9.3 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2019-2024)
        7.9.4 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product Offerings
        7.9.5 Jiangsu Hengrui Medicine Recent Development
    7.10 Juno Pharmaceuticals Pty Ltd.
        7.10.1 Juno Pharmaceuticals Pty Ltd. Company Information
        7.10.2 Juno Pharmaceuticals Pty Ltd. Introduction and Business Overview
        7.10.3 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2019-2024)
        7.10.4 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product Offerings
        7.10.5 Juno Pharmaceuticals Pty Ltd. Recent Development
    7.11 Medimmune, LLC
        7.11.1 Medimmune, LLC Company Information
        7.11.2 Medimmune, LLC Introduction and Business Overview
        7.11.3 Medimmune, LLC Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2019-2024)
        7.11.4 Medimmune, LLC Cancer Immunotherapy Drug Product Offerings
        7.11.5 Medimmune, LLC Recent Development
    7.12 Merck & Co., Inc.
        7.12.1 Merck & Co., Inc. Company Information
        7.12.2 Merck & Co., Inc. Introduction and Business Overview
        7.12.3 Merck & Co., Inc. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2019-2024)
        7.12.4 Merck & Co., Inc. Cancer Immunotherapy Drug Product Offerings
        7.12.5 Merck & Co., Inc. Recent Development
    7.13 Novartis AG
        7.13.1 Novartis AG Company Information
        7.13.2 Novartis AG Introduction and Business Overview
        7.13.3 Novartis AG Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2019-2024)
        7.13.4 Novartis AG Cancer Immunotherapy Drug Product Offerings
        7.13.5 Novartis AG Recent Development
    7.14 Pfizer, Inc.
        7.14.1 Pfizer, Inc. Company Information
        7.14.2 Pfizer, Inc. Introduction and Business Overview
        7.14.3 Pfizer, Inc. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2019-2024)
        7.14.4 Pfizer, Inc. Cancer Immunotherapy Drug Product Offerings
        7.14.5 Pfizer, Inc. Recent Development
    7.15 Roche Holding AG
        7.15.1 Roche Holding AG Company Information
        7.15.2 Roche Holding AG Introduction and Business Overview
        7.15.3 Roche Holding AG Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2019-2024)
        7.15.4 Roche Holding AG Cancer Immunotherapy Drug Product Offerings
        7.15.5 Roche Holding AG Recent Development

 8 Industry Chain Analysis
    8.1 Cancer Immunotherapy Drug Industrial Chain
    8.2 Cancer Immunotherapy Drug Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Cancer Immunotherapy Drug Sales Model
        8.5.2 Sales Channel
        8.5.3 Cancer Immunotherapy Drug Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Cancer Immunotherapy Drug Market Trends
    Table 2. Cancer Immunotherapy Drug Market Drivers & Opportunity
    Table 3. Cancer Immunotherapy Drug Market Challenges
    Table 4. Cancer Immunotherapy Drug Market Restraints
    Table 5. Global Cancer Immunotherapy Drug Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Cancer Immunotherapy Drug Revenue Market Share by Company (2019-2024)
    Table 7. Global Cancer Immunotherapy Drug Sales Volume by Company (2019-2024) & (K Units)
    Table 8. Global Cancer Immunotherapy Drug Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market Cancer Immunotherapy Drug Price by Company (2019-2024) & (US$/Unit)
    Table 10. Key Manufacturers Cancer Immunotherapy Drug Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers Cancer Immunotherapy Drug Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of Cancer Immunotherapy Drug
    Table 13. Global Cancer Immunotherapy Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Immunotherapy Drug as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Cancer Immunotherapy Drug Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global Cancer Immunotherapy Drug Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global Cancer Immunotherapy Drug Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global Cancer Immunotherapy Drug Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global Cancer Immunotherapy Drug Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global Cancer Immunotherapy Drug Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
    Table 22. Global Cancer Immunotherapy Drug Sales Volume by Type (2019-2024) & (K Units)
    Table 23. Global Cancer Immunotherapy Drug Sales Volume by Type (2025-2030) & (K Units)
    Table 24. Global Cancer Immunotherapy Drug Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global Cancer Immunotherapy Drug Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global Cancer Immunotherapy Drug Price by Type (2019-2024) & (US$/Unit)
    Table 27. Global Cancer Immunotherapy Drug Price by Type (2025-2030) & (US$/Unit)
    Table 28. Global Cancer Immunotherapy Drug Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global Cancer Immunotherapy Drug Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global Cancer Immunotherapy Drug Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global Cancer Immunotherapy Drug Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global Cancer Immunotherapy Drug Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global Cancer Immunotherapy Drug Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
    Table 34. Global Cancer Immunotherapy Drug Sales Volume by Application (2019-2024) & (K Units)
    Table 35. Global Cancer Immunotherapy Drug Sales Volume by Application (2025-2030) & (K Units)
    Table 36. Global Cancer Immunotherapy Drug Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global Cancer Immunotherapy Drug Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global Cancer Immunotherapy Drug Price by Application (2019-2024) & (US$/Unit)
    Table 39. Global Cancer Immunotherapy Drug Price by Application (2025-2030) & (US$/Unit)
    Table 40. Global Cancer Immunotherapy Drug Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global Cancer Immunotherapy Drug Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global Cancer Immunotherapy Drug Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global Cancer Immunotherapy Drug Sales Value by Region (2019-2024) & (%)
    Table 44. Global Cancer Immunotherapy Drug Sales Value by Region (2025-2030) & (%)
    Table 45. Global Cancer Immunotherapy Drug Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
    Table 46. Global Cancer Immunotherapy Drug Sales Volume by Region (2019-2024) & (K Units)
    Table 47. Global Cancer Immunotherapy Drug Sales Volume by Region (2025-2030) & (K Units)
    Table 48. Global Cancer Immunotherapy Drug Sales Volume by Region (2019-2024) & (%)
    Table 49. Global Cancer Immunotherapy Drug Sales Volume by Region (2025-2030) & (%)
    Table 50. Global Cancer Immunotherapy Drug Average Price by Region (2019-2024) & (US$/Unit)
    Table 51. Global Cancer Immunotherapy Drug Average Price by Region (2025-2030) & (US$/Unit)
    Table 52. Key Countries/Regions Cancer Immunotherapy Drug Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions Cancer Immunotherapy Drug Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions Cancer Immunotherapy Drug Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions Cancer Immunotherapy Drug Sales Volume, (2019-2024) & (K Units)
    Table 56. Key Countries/Regions Cancer Immunotherapy Drug Sales Volume, (2025-2030) & (K Units)
    Table 57. Autolus Therapeutics plc Company Information
    Table 58. Autolus Therapeutics plc Introduction and Business Overview
    Table 59. Autolus Therapeutics plc Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 60. Autolus Therapeutics plc Cancer Immunotherapy Drug Product Offerings
    Table 61. Autolus Therapeutics plc Recent Development
    Table 62. BeiGene Company Information
    Table 63. BeiGene Introduction and Business Overview
    Table 64. BeiGene Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 65. BeiGene Cancer Immunotherapy Drug Product Offerings
    Table 66. BeiGene Recent Development
    Table 67. bluebird bio, Inc. Company Information
    Table 68. bluebird bio, Inc. Introduction and Business Overview
    Table 69. bluebird bio, Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 70. bluebird bio, Inc. Cancer Immunotherapy Drug Product Offerings
    Table 71. bluebird bio, Inc. Recent Development
    Table 72. Bristol-Myers Squibb Company Information
    Table 73. Bristol-Myers Squibb Introduction and Business Overview
    Table 74. Bristol-Myers Squibb Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 75. Bristol-Myers Squibb Cancer Immunotherapy Drug Product Offerings
    Table 76. Bristol-Myers Squibb Recent Development
    Table 77. Celgene Corporation Company Information
    Table 78. Celgene Corporation Introduction and Business Overview
    Table 79. Celgene Corporation Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 80. Celgene Corporation Cancer Immunotherapy Drug Product Offerings
    Table 81. Celgene Corporation Recent Development
    Table 82. AstraZeneca plc Company Information
    Table 83. AstraZeneca plc Introduction and Business Overview
    Table 84. AstraZeneca plc Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 85. AstraZeneca plc Cancer Immunotherapy Drug Product Offerings
    Table 86. AstraZeneca plc Recent Development
    Table 87. Gilead Sciences, Inc. Company Information
    Table 88. Gilead Sciences, Inc. Introduction and Business Overview
    Table 89. Gilead Sciences, Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 90. Gilead Sciences, Inc. Cancer Immunotherapy Drug Product Offerings
    Table 91. Gilead Sciences, Inc. Recent Development
    Table 92. Incyte Corporation Company Information
    Table 93. Incyte Corporation Introduction and Business Overview
    Table 94. Incyte Corporation Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 95. Incyte Corporation Cancer Immunotherapy Drug Product Offerings
    Table 96. Incyte Corporation Recent Development
    Table 97. Jiangsu Hengrui Medicine Company Information
    Table 98. Jiangsu Hengrui Medicine Introduction and Business Overview
    Table 99. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 100. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product Offerings
    Table 101. Jiangsu Hengrui Medicine Recent Development
    Table 102. Juno Pharmaceuticals Pty Ltd. Company Information
    Table 103. Juno Pharmaceuticals Pty Ltd. Introduction and Business Overview
    Table 104. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 105. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product Offerings
    Table 106. Juno Pharmaceuticals Pty Ltd. Recent Development
    Table 107. Medimmune, LLC Company Information
    Table 108. Medimmune, LLC Introduction and Business Overview
    Table 109. Medimmune, LLC Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 110. Medimmune, LLC Cancer Immunotherapy Drug Product Offerings
    Table 111. Medimmune, LLC Recent Development
    Table 112. Merck & Co., Inc. Company Information
    Table 113. Merck & Co., Inc. Introduction and Business Overview
    Table 114. Merck & Co., Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 115. Merck & Co., Inc. Cancer Immunotherapy Drug Product Offerings
    Table 116. Merck & Co., Inc. Recent Development
    Table 117. Novartis AG Company Information
    Table 118. Novartis AG Introduction and Business Overview
    Table 119. Novartis AG Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 120. Novartis AG Cancer Immunotherapy Drug Product Offerings
    Table 121. Novartis AG Recent Development
    Table 122. Pfizer, Inc. Company Information
    Table 123. Pfizer, Inc. Introduction and Business Overview
    Table 124. Pfizer, Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 125. Pfizer, Inc. Cancer Immunotherapy Drug Product Offerings
    Table 126. Pfizer, Inc. Recent Development
    Table 127. Roche Holding AG Company Information
    Table 128. Roche Holding AG Introduction and Business Overview
    Table 129. Roche Holding AG Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 130. Roche Holding AG Cancer Immunotherapy Drug Product Offerings
    Table 131. Roche Holding AG Recent Development
    Table 132. Key Raw Materials Lists
    Table 133. Raw Materials Key Suppliers Lists
    Table 134. Cancer Immunotherapy Drug Downstream Customers
    Table 135. Cancer Immunotherapy Drug Distributors List
    Table 136. Research Programs/Design for This Report
    Table 137. Key Data Information from Secondary Sources
    Table 138. Key Data Information from Primary Sources
List of Figures
    Figure 1. Cancer Immunotherapy Drug Product Picture
    Figure 2. Global Cancer Immunotherapy Drug Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Cancer Immunotherapy Drug Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global Cancer Immunotherapy Drug Sales Volume (2019-2030) & (K Units)
    Figure 5. Global Cancer Immunotherapy Drug Sales Price (2019-2030) & (US$/Unit)
    Figure 6. Cancer Immunotherapy Drug Report Years Considered
    Figure 7. Global Cancer Immunotherapy Drug Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global Cancer Immunotherapy Drug Players Sales Volume Ranking (2023) & (K Units)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Cancer Immunotherapy Drug Revenue in 2023
    Figure 10. Cancer Immunotherapy Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. PD-1 Inhibitor Picture
    Figure 12. PDL-1 Inhibitor Picture
    Figure 13. T-Cell Stimulant Picture
    Figure 14. CTLA Antibody Picture
    Figure 15. Global Cancer Immunotherapy Drug Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 16. Global Cancer Immunotherapy Drug Sales Value Market Share by Type, 2023 & 2030
    Figure 17. Global Cancer Immunotherapy Drug Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
    Figure 18. Global Cancer Immunotherapy Drug Sales Volume Market Share by Type, 2023 & 2030
    Figure 19. Global Cancer Immunotherapy Drug Price by Type (2019-2030) & (US$/Unit)
    Figure 20. Product Picture of Hospital
    Figure 21. Product Picture of Clinic
    Figure 22. Product Picture of Others
    Figure 23. Global Cancer Immunotherapy Drug Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 24. Global Cancer Immunotherapy Drug Sales Value Market Share by Application, 2023 & 2030
    Figure 25. Global Cancer Immunotherapy Drug Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
    Figure 26. Global Cancer Immunotherapy Drug Sales Volume Market Share by Application, 2023 & 2030
    Figure 27. Global Cancer Immunotherapy Drug Price by Application (2019-2030) & (US$/Unit)
    Figure 28. North America Cancer Immunotherapy Drug Sales Value (2019-2030) & (US$ Million)
    Figure 29. North America Cancer Immunotherapy Drug Sales Value by Country (%), 2023 VS 2030
    Figure 30. Europe Cancer Immunotherapy Drug Sales Value (2019-2030) & (US$ Million)
    Figure 31. Europe Cancer Immunotherapy Drug Sales Value by Country (%), 2023 VS 2030
    Figure 32. Asia Pacific Cancer Immunotherapy Drug Sales Value (2019-2030) & (US$ Million)
    Figure 33. Asia Pacific Cancer Immunotherapy Drug Sales Value by Country (%), 2023 VS 2030
    Figure 34. South America Cancer Immunotherapy Drug Sales Value (2019-2030) & (US$ Million)
    Figure 35. South America Cancer Immunotherapy Drug Sales Value by Country (%), 2023 VS 2030
    Figure 36. Middle East & Africa Cancer Immunotherapy Drug Sales Value (2019-2030) & (US$ Million)
    Figure 37. Middle East & Africa Cancer Immunotherapy Drug Sales Value by Country (%), 2023 VS 2030
    Figure 38. Key Countries/Regions Cancer Immunotherapy Drug Sales Value (%), (2019-2030)
    Figure 39. Key Countries/Regions Cancer Immunotherapy Drug Sales Volume (%), (2019-2030)
    Figure 40. United States Cancer Immunotherapy Drug Sales Value, (2019-2030) & (US$ Million)
    Figure 41. United States Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
    Figure 42. United States Cancer Immunotherapy Drug Sales Value by Application (%), 2023 VS 2030
    Figure 43. Europe Cancer Immunotherapy Drug Sales Value, (2019-2030) & (US$ Million)
    Figure 44. Europe Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
    Figure 45. Europe Cancer Immunotherapy Drug Sales Value by Application (%), 2023 VS 2030
    Figure 46. China Cancer Immunotherapy Drug Sales Value, (2019-2030) & (US$ Million)
    Figure 47. China Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
    Figure 48. China Cancer Immunotherapy Drug Sales Value by Application (%), 2023 VS 2030
    Figure 49. Japan Cancer Immunotherapy Drug Sales Value, (2019-2030) & (US$ Million)
    Figure 50. Japan Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
    Figure 51. Japan Cancer Immunotherapy Drug Sales Value by Application (%), 2023 VS 2030
    Figure 52. South Korea Cancer Immunotherapy Drug Sales Value, (2019-2030) & (US$ Million)
    Figure 53. South Korea Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
    Figure 54. South Korea Cancer Immunotherapy Drug Sales Value by Application (%), 2023 VS 2030
    Figure 55. Southeast Asia Cancer Immunotherapy Drug Sales Value, (2019-2030) & (US$ Million)
    Figure 56. Southeast Asia Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
    Figure 57. Southeast Asia Cancer Immunotherapy Drug Sales Value by Application (%), 2023 VS 2030
    Figure 58. India Cancer Immunotherapy Drug Sales Value, (2019-2030) & (US$ Million)
    Figure 59. India Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
    Figure 60. India Cancer Immunotherapy Drug Sales Value by Application (%), 2023 VS 2030
    Figure 61. Cancer Immunotherapy Drug Industrial Chain
    Figure 62. Cancer Immunotherapy Drug Manufacturing Cost Structure
    Figure 63. Channels of Distribution (Direct Sales, and Distribution)
    Figure 64. Bottom-up and Top-down Approaches for This Report
    Figure 65. Data Triangulation
    Figure 66. Key Executives Interviewed

Description

Cancer Immunotherapy Drugs are medications used in the treatment of cancer. These drugs harness the body's immune system to target and destroy cancer cells. Immunotherapy drugs are designed to boost the body's natural defenses against cancer and are used in various forms, including immune checkpoint inhibitors and CAR-T cell therapies.

The global market for Cancer Immunotherapy Drug was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

Market Segmentation